{"DataElement":{"publicId":"2554877","version":"1","preferredName":"Inoperable Malignant Neoplasm Present Ind-2","preferredDefinition":"the yes/no indicator related to a malignant neoplasm that is not suitable for surgery.","longName":"INOP_MALIGN_PRES_IND","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2554879","version":"1","preferredName":"Inoperable Malignant Neoplasm Present","preferredDefinition":"information related to a tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues being present that is not suitable for surgery.","longName":"INOP_MALIGNEO_PRES","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2583543","version":"1","preferredName":"Inoperable Malignant Neoplasm","preferredDefinition":"Not suitable for surgery.:A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004","longName":"C64247:C9305","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inoperable","conceptCode":"C64247","definition":"Not suitable for surgery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2596906E-4711-30E5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-12-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-12-27","modifiedBy":"ONEDATA","dateModified":"2006-12-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233878","version":"1","preferredName":"Present","preferredDefinition":"Being or existing in a specified place or at the specified time.","longName":"C25626","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Present","conceptCode":"C25626","definition":"Being or existing in a specified place or at the specified time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F970CDF6-F829-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"ONEDATA","dateModified":"2005-06-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24AD6157-760B-54CA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-12-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-12-15","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2812156","version":"1","longName":"Breast Cancer DataMart","context":"CTEP"}]},{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4104933","version":"1","longName":"RTOG-1308","context":"NRG"},{"publicId":"4104937","version":"1","longName":"RTOG-1306","context":"NRG"},{"publicId":"4104994","version":"1","longName":"RTOG-1201","context":"NRG"}]}],"AlternateNames":[{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"INOP_MALIGN_PRES_IND","type":"USED_BY","context":"NRG"},{"name":"INOP_MALIGN_PRES_IND","type":"USED_BY","context":"CITN"},{"name":"Alliance","type":"USED_BY","context":"Alliance"},{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"Is patient unresectable or in","type":"Preferred Question Text","description":"Is patient unresectable or inoperable","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Is the tumor inoperable or unresectable","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Has disease been deemed unresectable by a qualified surgeon","url":null,"context":"CTEP"},{"name":"CRF Text 3","type":"Alternate Question Text","description":"Has the tumor been determined to be unresectable by  pancreas protocol CT or MRI ?","url":null,"context":"CTEP"},{"name":"CRF Text 4","type":"Alternate Question Text","description":"Has the tumor been determined to be unresectable at the time of surgical exploration?","url":null,"context":"CTEP"},{"name":"CRF Text 5","type":"Alternate Question Text","description":"Unresectable stage III or IV validated by clinical criteria (including recurrent melanoma), or patients with multiple skin/soft tissue metastases that may be resectable but are judged to have a future recurrence risk exceeding 90% (e.g., multiple in-transit melanoma metastases).  Tumor deemed amendable to biopsy (excisional, incisional, or core, with at least 100 mm^3 tumor volume per biopsy date) and fine-needle aspirations (FNA) biopsy.  Stage IV no evidence of disease (NED) is excluded by this criterion.","url":null,"context":"CTEP"},{"name":"CRF Text 6","type":"Alternate Question Text","description":"Does the patient have unresectable disease, are they medically inoperable, or are they unwilling to undergo surgical management?","url":null,"context":"NRG"},{"name":"COG CRF TEXT 1","type":"Alternate Question Text","description":"Does patient have initially unresectable disease?","url":null,"context":"CTEP"},{"name":"CITN","type":"Alternate Question Text","description":"Unresectable stage III or IV validated by clinical criteria (including recurrent melanoma), or patients with multiple skin/soft tissue metastases of melanoma that may be resectable but are judged to have a future recurrence risk exceeding 90% (e.g., distant skin metastases or multiple in-transit melanoma metastases). Tumor deemed amendable to biopsy (excisional, incisional, or core, with at least 100 mm^3 tumor volume per biopsy date) and fine-needle aspirations (FNA) biopsy. Stage IV no evidence of disease (NED) is excluded by this criterion.","url":null,"context":"CITN"},{"name":"CITN text","type":"Alternate Question Text","description":"Unresectable stage III or IV validated by clinical criteria (including recurrent melanoma), or patients with multiple skin/soft tissue metastases of melanoma that may be resectable but are judged to have a future recurrence risk exceeding 70% (e.g., large adenopathy, distant skin metastases or multiple in-transit melanoma metastases). Tumor deemed amendable to biopsy (excisional, incisional, or core, with at least 100 mm^3 tumor volume per biopsy date) and fine-needle aspirations (FNA) biopsy. Stage IV no evidence of disease (NED) is excluded by this criterion.","url":null,"context":"CITN"},{"name":"CITN Text 1","type":"Alternate Question Text","description":"Unresectable stage III or IV melanoma validated by clinical criteria (including recurrent melanoma), or patients with multiple skin/soft tissue metastases of melanoma that may be resectable but are judged to have a future recurrence risk exceeding 90% (e.g., distant skin metastases or multiple in-transit melanoma metastases). Tumor deemed amendable to biopsy (excisional, incisional, or core, with at least 100 mm^3 tumor volume per biopsy date) and fine-needle aspirations (FNA) biopsy. Stage IV no evidence of disease (NED) is excluded by this criterion.","url":null,"context":"CITN"},{"name":"CITN Text 2","type":"Alternate Question Text","description":"Unresectable stage III or IV melanoma validated by clinical criteria (including recurrent melanoma), or patients with multiple skin/soft tissue metastases of melanoma that may be resectable but are judged to have a future recurrence risk exceeding 70% (e.g., large adenopathy, distant skin metastases or multiple in-transit melanoma metastases). Tumor deemed amendable to biopsy (excisional, incisional, or core, with at least 100 mm^3 tumor volume per biopsy date) and fine-needle aspirations (FNA) biopsy. Stage IV no evidence of disease (NED) is excluded by this criterion.","url":null,"context":"CITN"},{"name":"CRF Text 7","type":"Alternate Question Text","description":"Is the patient, in the opinion of a thoracic surgeon and/or multidisciplinary team, not a candidate for surgery?","url":null,"context":"NRG"},{"name":"CRF Text8","type":"Alternate Question Text","description":"is disease considered unresectable?","url":null,"context":"Alliance"},{"name":"CRF Text 9","type":"Alternate Question Text","description":"Is the patient, in the opinion of a thoracic surgeon and/or multidisciplinary team, not a candidate for surgery but is a candidate for chemoradiation?","url":null,"context":"NRG"},{"name":"Does the patient have unresectable primary tumor?","type":"Alternate Question Text","description":"Does the patient have unresectable primary tumor?","url":null,"context":"COG"},{"name":"CRF Text 10","type":"Alternate Question Text","description":"Is the patient, in the opinion of the surgeon, not a candidate for pelvic lymphadenectomy?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text","type":"Alternate Question Text","description":"Is the disease considered unresectable via primary debulking surgery and in need of neoadjuvant chemotherapy (NCAT) prior to debulking surgery?","url":null,"context":"NRG"},{"name":"NRG CRF Text 1","type":"Alternate Question Text","description":"Is the patient a candidate for whom non-operative management is a viable option, in the opinion of a thoracic surgeon and/or multidisciplinary team, and is a candidate for chemoradiation","url":null,"context":"NRG"}],"origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"24AD625F-DB88-57CA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-12-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-12-15","modifiedBy":"TSESU","dateModified":"2023-06-20","changeDescription":"Replaced VD Involvement Extent Disease Ind-2 - 2180012v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}